Efficacy of oral telithromycin in community-acquired pneumonia caused by resistant Streptococcus pneumoniae
The efficacy of oral telithromycin 800 mg once daily for 7 days was evaluated in a multicentre, multinational study in patients with community-acquired pneumonia caused by Streptococcus pneumoniae resistant to penicillin and/or erythromycin. Per-protocol clinical and bacteriological outcomes were as...
Gespeichert in:
| Veröffentlicht in: | The Journal of infection 2005-10, Vol.51 (3), p.201-205 |
|---|---|
| Hauptverfasser: | , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 205 |
|---|---|
| container_issue | 3 |
| container_start_page | 201 |
| container_title | The Journal of infection |
| container_volume | 51 |
| creator | van Rensburg, Dirkie Fogarty, Charles De Salvo, María Cristina Rangaraju, Manickam Nusrat, Roomi |
| description | The efficacy of oral telithromycin 800
mg once daily for 7 days was evaluated in a multicentre, multinational study in patients with community-acquired pneumonia caused by
Streptococcus pneumoniae resistant to penicillin and/or erythromycin. Per-protocol clinical and bacteriological outcomes were assessed 10–17 days post-therapy. Of the 129 patients with
S. pneumoniae infection, 16 were infected with strains resistant to penicillin and/or erythromycin. Fifteen of these 16 patients (93.8%) were assessed as clinically and bacteriologically cured at the post-therapy visit. |
| doi_str_mv | 10.1016/j.jinf.2004.11.004 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_68706510</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><els_id>S0163445304002580</els_id><sourcerecordid>68706510</sourcerecordid><originalsourceid>FETCH-LOGICAL-c415t-643daa5e3856e235aa561989a8337cd171237546645cdca9eb328c87db51db3e3</originalsourceid><addsrcrecordid>eNqFkU2L1EAQhhtR3HH0D3iQXPSW2N9JwIssq7uw4EE9N53qCvaYpGe7O0L-vT3MwNwUCt6ieOqDegl5y2jDKNMfD83BL2PDKZUNY02RZ2THlOA1byV_TnYFErWUStyQVykdKKW96PVLcsM0F5QzvSO_78bRg4WtCmMVop2qjJPPv2KYN_BLVQLCPK-Lz1tt4Wn1EV11XHCdw-JtBXZNpTBsVcTkU7ZLrr7niMccIACs6cria_JitFPCNxfdk59f7n7c3teP374-3H5-rEEylWsthbNWoeiURi5UyTXru952QrTgWMu4aJXUWipwYHscBO-ga92gmBsEij35cJ57jOFpxZTN7BPgNNkFw5qM7lqqFaP_BTntOFNl3Z7wMwgxpBRxNMfoZxs3w6g5eWEO5uSFOXlhGDNFStO7y_R1mNFdWy7PL8D7C2AT2GmMdgGfrlzLpeJcFO7TmcPytD8eo0ngcQF0xQzIxgX_rzv-Amc7qR0</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>20821512</pqid></control><display><type>article</type><title>Efficacy of oral telithromycin in community-acquired pneumonia caused by resistant Streptococcus pneumoniae</title><source>MEDLINE</source><source>Elsevier ScienceDirect Journals</source><creator>van Rensburg, Dirkie ; Fogarty, Charles ; De Salvo, María Cristina ; Rangaraju, Manickam ; Nusrat, Roomi</creator><creatorcontrib>van Rensburg, Dirkie ; Fogarty, Charles ; De Salvo, María Cristina ; Rangaraju, Manickam ; Nusrat, Roomi</creatorcontrib><description>The efficacy of oral telithromycin 800
mg once daily for 7 days was evaluated in a multicentre, multinational study in patients with community-acquired pneumonia caused by
Streptococcus pneumoniae resistant to penicillin and/or erythromycin. Per-protocol clinical and bacteriological outcomes were assessed 10–17 days post-therapy. Of the 129 patients with
S. pneumoniae infection, 16 were infected with strains resistant to penicillin and/or erythromycin. Fifteen of these 16 patients (93.8%) were assessed as clinically and bacteriologically cured at the post-therapy visit.</description><identifier>ISSN: 0163-4453</identifier><identifier>EISSN: 1532-2742</identifier><identifier>DOI: 10.1016/j.jinf.2004.11.004</identifier><identifier>PMID: 16230216</identifier><identifier>CODEN: JINFD2</identifier><language>eng</language><publisher>Kidlington: Elsevier Ltd</publisher><subject>Administration, Oral ; Adult ; Aged ; Anti-Bacterial Agents - administration & dosage ; Anti-Bacterial Agents - pharmacology ; Anti-Bacterial Agents - therapeutic use ; Antibacterial agents ; Antibiotic resistance ; Antibiotics. Antiinfectious agents. Antiparasitic agents ; Bacterial diseases ; Biological and medical sciences ; Community-Acquired Infections - drug therapy ; Community-Acquired Infections - microbiology ; Community-acquired pneumonia ; Drug Resistance, Bacterial ; Erythromycin - pharmacology ; Female ; Human bacterial diseases ; Humans ; Infectious diseases ; Ketolides - administration & dosage ; Ketolides - therapeutic use ; Male ; Medical sciences ; Microbial Sensitivity Tests ; Middle Aged ; Penicillin Resistance ; Penicillins - pharmacology ; Pharmacology. Drug treatments ; Pneumonia, Pneumococcal - drug therapy ; Pneumonia, Pneumococcal - microbiology ; Staphylococcal infections, streptococcal infections, pneumococcal infections ; Streptococcus pneumoniae ; Telithromycin ; Treatment Outcome</subject><ispartof>The Journal of infection, 2005-10, Vol.51 (3), p.201-205</ispartof><rights>2005</rights><rights>2005 INIST-CNRS</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c415t-643daa5e3856e235aa561989a8337cd171237546645cdca9eb328c87db51db3e3</citedby><cites>FETCH-LOGICAL-c415t-643daa5e3856e235aa561989a8337cd171237546645cdca9eb328c87db51db3e3</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktohtml>$$Uhttps://dx.doi.org/10.1016/j.jinf.2004.11.004$$EHTML$$P50$$Gelsevier$$H</linktohtml><link.rule.ids>314,778,782,3539,27907,27908,45978</link.rule.ids><backlink>$$Uhttp://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&idt=17245223$$DView record in Pascal Francis$$Hfree_for_read</backlink><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/16230216$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>van Rensburg, Dirkie</creatorcontrib><creatorcontrib>Fogarty, Charles</creatorcontrib><creatorcontrib>De Salvo, María Cristina</creatorcontrib><creatorcontrib>Rangaraju, Manickam</creatorcontrib><creatorcontrib>Nusrat, Roomi</creatorcontrib><title>Efficacy of oral telithromycin in community-acquired pneumonia caused by resistant Streptococcus pneumoniae</title><title>The Journal of infection</title><addtitle>J Infect</addtitle><description>The efficacy of oral telithromycin 800
mg once daily for 7 days was evaluated in a multicentre, multinational study in patients with community-acquired pneumonia caused by
Streptococcus pneumoniae resistant to penicillin and/or erythromycin. Per-protocol clinical and bacteriological outcomes were assessed 10–17 days post-therapy. Of the 129 patients with
S. pneumoniae infection, 16 were infected with strains resistant to penicillin and/or erythromycin. Fifteen of these 16 patients (93.8%) were assessed as clinically and bacteriologically cured at the post-therapy visit.</description><subject>Administration, Oral</subject><subject>Adult</subject><subject>Aged</subject><subject>Anti-Bacterial Agents - administration & dosage</subject><subject>Anti-Bacterial Agents - pharmacology</subject><subject>Anti-Bacterial Agents - therapeutic use</subject><subject>Antibacterial agents</subject><subject>Antibiotic resistance</subject><subject>Antibiotics. Antiinfectious agents. Antiparasitic agents</subject><subject>Bacterial diseases</subject><subject>Biological and medical sciences</subject><subject>Community-Acquired Infections - drug therapy</subject><subject>Community-Acquired Infections - microbiology</subject><subject>Community-acquired pneumonia</subject><subject>Drug Resistance, Bacterial</subject><subject>Erythromycin - pharmacology</subject><subject>Female</subject><subject>Human bacterial diseases</subject><subject>Humans</subject><subject>Infectious diseases</subject><subject>Ketolides - administration & dosage</subject><subject>Ketolides - therapeutic use</subject><subject>Male</subject><subject>Medical sciences</subject><subject>Microbial Sensitivity Tests</subject><subject>Middle Aged</subject><subject>Penicillin Resistance</subject><subject>Penicillins - pharmacology</subject><subject>Pharmacology. Drug treatments</subject><subject>Pneumonia, Pneumococcal - drug therapy</subject><subject>Pneumonia, Pneumococcal - microbiology</subject><subject>Staphylococcal infections, streptococcal infections, pneumococcal infections</subject><subject>Streptococcus pneumoniae</subject><subject>Telithromycin</subject><subject>Treatment Outcome</subject><issn>0163-4453</issn><issn>1532-2742</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2005</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNqFkU2L1EAQhhtR3HH0D3iQXPSW2N9JwIssq7uw4EE9N53qCvaYpGe7O0L-vT3MwNwUCt6ieOqDegl5y2jDKNMfD83BL2PDKZUNY02RZ2THlOA1byV_TnYFErWUStyQVykdKKW96PVLcsM0F5QzvSO_78bRg4WtCmMVop2qjJPPv2KYN_BLVQLCPK-Lz1tt4Wn1EV11XHCdw-JtBXZNpTBsVcTkU7ZLrr7niMccIACs6cria_JitFPCNxfdk59f7n7c3teP374-3H5-rEEylWsthbNWoeiURi5UyTXru952QrTgWMu4aJXUWipwYHscBO-ga92gmBsEij35cJ57jOFpxZTN7BPgNNkFw5qM7lqqFaP_BTntOFNl3Z7wMwgxpBRxNMfoZxs3w6g5eWEO5uSFOXlhGDNFStO7y_R1mNFdWy7PL8D7C2AT2GmMdgGfrlzLpeJcFO7TmcPytD8eo0ngcQF0xQzIxgX_rzv-Amc7qR0</recordid><startdate>20051001</startdate><enddate>20051001</enddate><creator>van Rensburg, Dirkie</creator><creator>Fogarty, Charles</creator><creator>De Salvo, María Cristina</creator><creator>Rangaraju, Manickam</creator><creator>Nusrat, Roomi</creator><general>Elsevier Ltd</general><general>Elsevier</general><scope>IQODW</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7QL</scope><scope>C1K</scope><scope>7X8</scope></search><sort><creationdate>20051001</creationdate><title>Efficacy of oral telithromycin in community-acquired pneumonia caused by resistant Streptococcus pneumoniae</title><author>van Rensburg, Dirkie ; Fogarty, Charles ; De Salvo, María Cristina ; Rangaraju, Manickam ; Nusrat, Roomi</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c415t-643daa5e3856e235aa561989a8337cd171237546645cdca9eb328c87db51db3e3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2005</creationdate><topic>Administration, Oral</topic><topic>Adult</topic><topic>Aged</topic><topic>Anti-Bacterial Agents - administration & dosage</topic><topic>Anti-Bacterial Agents - pharmacology</topic><topic>Anti-Bacterial Agents - therapeutic use</topic><topic>Antibacterial agents</topic><topic>Antibiotic resistance</topic><topic>Antibiotics. Antiinfectious agents. Antiparasitic agents</topic><topic>Bacterial diseases</topic><topic>Biological and medical sciences</topic><topic>Community-Acquired Infections - drug therapy</topic><topic>Community-Acquired Infections - microbiology</topic><topic>Community-acquired pneumonia</topic><topic>Drug Resistance, Bacterial</topic><topic>Erythromycin - pharmacology</topic><topic>Female</topic><topic>Human bacterial diseases</topic><topic>Humans</topic><topic>Infectious diseases</topic><topic>Ketolides - administration & dosage</topic><topic>Ketolides - therapeutic use</topic><topic>Male</topic><topic>Medical sciences</topic><topic>Microbial Sensitivity Tests</topic><topic>Middle Aged</topic><topic>Penicillin Resistance</topic><topic>Penicillins - pharmacology</topic><topic>Pharmacology. Drug treatments</topic><topic>Pneumonia, Pneumococcal - drug therapy</topic><topic>Pneumonia, Pneumococcal - microbiology</topic><topic>Staphylococcal infections, streptococcal infections, pneumococcal infections</topic><topic>Streptococcus pneumoniae</topic><topic>Telithromycin</topic><topic>Treatment Outcome</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>van Rensburg, Dirkie</creatorcontrib><creatorcontrib>Fogarty, Charles</creatorcontrib><creatorcontrib>De Salvo, María Cristina</creatorcontrib><creatorcontrib>Rangaraju, Manickam</creatorcontrib><creatorcontrib>Nusrat, Roomi</creatorcontrib><collection>Pascal-Francis</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>Bacteriology Abstracts (Microbiology B)</collection><collection>Environmental Sciences and Pollution Management</collection><collection>MEDLINE - Academic</collection><jtitle>The Journal of infection</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>van Rensburg, Dirkie</au><au>Fogarty, Charles</au><au>De Salvo, María Cristina</au><au>Rangaraju, Manickam</au><au>Nusrat, Roomi</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Efficacy of oral telithromycin in community-acquired pneumonia caused by resistant Streptococcus pneumoniae</atitle><jtitle>The Journal of infection</jtitle><addtitle>J Infect</addtitle><date>2005-10-01</date><risdate>2005</risdate><volume>51</volume><issue>3</issue><spage>201</spage><epage>205</epage><pages>201-205</pages><issn>0163-4453</issn><eissn>1532-2742</eissn><coden>JINFD2</coden><abstract>The efficacy of oral telithromycin 800
mg once daily for 7 days was evaluated in a multicentre, multinational study in patients with community-acquired pneumonia caused by
Streptococcus pneumoniae resistant to penicillin and/or erythromycin. Per-protocol clinical and bacteriological outcomes were assessed 10–17 days post-therapy. Of the 129 patients with
S. pneumoniae infection, 16 were infected with strains resistant to penicillin and/or erythromycin. Fifteen of these 16 patients (93.8%) were assessed as clinically and bacteriologically cured at the post-therapy visit.</abstract><cop>Kidlington</cop><pub>Elsevier Ltd</pub><pmid>16230216</pmid><doi>10.1016/j.jinf.2004.11.004</doi><tpages>5</tpages></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0163-4453 |
| ispartof | The Journal of infection, 2005-10, Vol.51 (3), p.201-205 |
| issn | 0163-4453 1532-2742 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_68706510 |
| source | MEDLINE; Elsevier ScienceDirect Journals |
| subjects | Administration, Oral Adult Aged Anti-Bacterial Agents - administration & dosage Anti-Bacterial Agents - pharmacology Anti-Bacterial Agents - therapeutic use Antibacterial agents Antibiotic resistance Antibiotics. Antiinfectious agents. Antiparasitic agents Bacterial diseases Biological and medical sciences Community-Acquired Infections - drug therapy Community-Acquired Infections - microbiology Community-acquired pneumonia Drug Resistance, Bacterial Erythromycin - pharmacology Female Human bacterial diseases Humans Infectious diseases Ketolides - administration & dosage Ketolides - therapeutic use Male Medical sciences Microbial Sensitivity Tests Middle Aged Penicillin Resistance Penicillins - pharmacology Pharmacology. Drug treatments Pneumonia, Pneumococcal - drug therapy Pneumonia, Pneumococcal - microbiology Staphylococcal infections, streptococcal infections, pneumococcal infections Streptococcus pneumoniae Telithromycin Treatment Outcome |
| title | Efficacy of oral telithromycin in community-acquired pneumonia caused by resistant Streptococcus pneumoniae |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-17T00%3A42%3A18IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Efficacy%20of%20oral%20telithromycin%20in%20community-acquired%20pneumonia%20caused%20by%20resistant%20Streptococcus%20pneumoniae&rft.jtitle=The%20Journal%20of%20infection&rft.au=van%20Rensburg,%20Dirkie&rft.date=2005-10-01&rft.volume=51&rft.issue=3&rft.spage=201&rft.epage=205&rft.pages=201-205&rft.issn=0163-4453&rft.eissn=1532-2742&rft.coden=JINFD2&rft_id=info:doi/10.1016/j.jinf.2004.11.004&rft_dat=%3Cproquest_cross%3E68706510%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=20821512&rft_id=info:pmid/16230216&rft_els_id=S0163445304002580&rfr_iscdi=true |